Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC

被引：0
|
作者：
Neninger, E. [1 ]
Caceres, H. [1 ]
Camacho, K. [2 ]
Hernandez, M. [3 ]
Santiesteban, E. [2 ]
Del Castillo, C. [4 ]
Menendez, Y. [4 ]
Gonzalez, B. [5 ]
机构：
[1] Hermanos Ameijeiras Hosp, Clin Oncol, Havana, Cuba
[2] Jose Ramon Lopez Hosp, Clin Oncol, Matanzas, Cuba
[3] Mol Immunol Ctr, Havana, Cuba
[4] Hermanos Ameijeiras Hosp, Radiotherapy, Havana, Cuba
[5] Ramon Lopez Tabranes Hosp, Matanzas, Cuba
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Cimavax Egf vaccine; IIIa NSCLC; immunogenicity;
D O I：
10.1016/j.jtho.2019.08.1435
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-92
引用
收藏
页码：S676 / S677
页数：2
相关论文
共 50 条
  • [21] Docetaxel and cisplatin as first-line chemotherapy in advanced NSCLC.
    Behera, D
    Aggarwal, AN
    Gupta, D
    Jindal, SK
    Sharma, SC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 705S - 705S
  • [22] The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer - A phase I-II study
    Zamagni, C
    Martoni, A
    Cacciari, N
    Gentile, A
    Pannuti, F
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (05): : 491 - 497
  • [23] Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
    Gadgeel, Shirish
    Gandhi, Leena
    Borghaei, Hossein
    Socinski, Mark A.
    Gubens, Matthew A.
    Stevenson, James
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    Papadimitrakopoulou, Vassiliki
    Bourque, Jennifer
    Bachman, Robert D.
    Ge, Joy Yang
    Im, Ellie
    Patnaik, Amita
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S428 - S428
  • [24] Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy for First-Line Treatment of Advanced Non-Squamous NSCLC
    Thein, K.
    Jahan, N.
    Sultan, A.
    Swarup, S.
    Tun, A.
    Yendala, R.
    Ball, S.
    Hlaing, P.
    Htut, T.
    Rehman, S.
    D'Cunha, N.
    Hardwicke, F.
    Tijani, L.
    Awasthi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S472 - S473
  • [25] Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
    OuYang, Pu-Yun
    Su, Zhen
    Mao, Yan-Ping
    Deng, Wuguo
    Xie, Fang-Yun
    PLOS ONE, 2013, 8 (11):
  • [26] First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Jotte, Robert M.
    Socinski, Mark A.
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    West, Howard J.
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Cappuzzo, Federico
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S302 - S303
  • [27] First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Cappuzzo, Frederico
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    Jotte, Robert
    West, Howard
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Socinski, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1296 - S1297
  • [28] A first for first-line therapy in NSCLC
    Rebecca Kirk
    Nature Reviews Clinical Oncology, 2011, 8 (12) : 691 - 691
  • [29] Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer
    Meyerhardt, Jeffrey A.
    Li, Ling
    Sanoff, Hanna K.
    Carpenter, William
    Schrag, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 608 - 615
  • [30] A Phase II Trial of Pictilisib with Chemotherapy in First-Line Squamous NSCLC
    Spigel, David
    Luft, Alexander
    Vynnychenko, Ihor
    Fadeeva, Natalia
    Mark, Zsuzsanna
    Ponce, Santiago
    Matrosova, Marina
    Goldschmidt, Jerome
    Szima, Barna
    Saleh, Mansoor
    Lackner, Mark
    Gendreau, Steve
    Bassett, Katia
    Spoerke, Jill
    Koeppen, Hartmut
    Gilbert, Houston
    Jin, Huan
    Shankar, Geetha
    Lin, Wei
    Denis, Fabrice
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S375 - S375
12345